Drugs

Zeynep Irem Ozay: Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US

Zeynep Irem Ozay/X

Mar 22, 2025, 13:05

Zeynep Irem Ozay: Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US

Zeynep Irem Ozay, Postdoctoral Research Fellow at Huntsman Cancer Institute, shared an article she and her colleagues authored on X:

“Just in JAMA Network Open.

Real world Treatment data from >8500 patients with mRCC kidney cancer.

After 2018, only 38% and 14% of patients received 2nd and 3rd line treatment respectively.

Thanks to my mentors.”

Treatment and Attrition Trends for Metastatic Clear Cell Renal Cell Carcinoma in the US

Authors: Zeynep Irem Ozay et al.

renal cell carcinoma

Benjamin L Maughan cancer Chadi Hage Chehade Clear cell renal cell carcinoma (ccRCC) Ethan Anderson Georges Gebrael Gliceida Galarza Fortuna Metastatic Clear Cell Renal Cell Carcinoma Micah Ostrowski Miguel Zugman Neeraj Agarwal Nicolas Sayegh OncoDaily Oncology Salvador Jaime-Casas Sumanta K. Pal Umang Swami Vinay Mathew Thomas Yeonjung Jo Zeynep Irem Ozay

Top GU Immunotherapy Trials to Watch at ESMO 2025

Hagop Kantarjian: Advances and Revolution in Adult ALL Therapy Over the Last Decade

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Top 10 Immunotherapy Fellowships and Grants to Watch in 2025

July Is Sarcoma Awareness Month: What You Need to Know